update on compounded semaglutide Despite FDA ruling, GLP-1s are still giving Novo and Lilly headaches the market Compounded Semaglutide for Weight Loss
Description
All three drugs share the same common active ingredient: semaglutide

Pediatric obesity-assessment, treatment, and prevention: an Endocrine Society clinical practice guideline

A well-known GLP-1 RA, semaglutide, is approved by the FDA for the treatment of type 2 diabetes under the brand names Ozempic and Rybelsus

Risk varies: Prior stones, diet, and fluid intake matter greatly
